<div id="readability-page-1"><p>In a report released today, Dara Azar from Stifel Nicolaus reiterated a Buy rating on Inhibrx Biosciences Inc, with a price target of <span id="expert-recommendation-target">$325.00</span>.</p><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with  Smart Investor Picks  </li></ul> <p>According to TipRanks, Azar is a 2-star analyst with an average return of <span>27.3%</span> and a 66.67% success rate.</p> <p>In a report released on May 11, LifeSci Capital also maintained a Buy rating on the stock with a $230.00 price target.</p></div>

INBX

SBIO

LABU

IBBQ

<p>Stifel Nicolaus has maintained a Buy rating for Inhibrx Biosciences Inc (INBX) with a price target of $325.00. Analyst Dara Azar, noted for a 27.3% average return, follows a similar Buy rating from LifeSci Capital, which set a price target of $230.00.</p>

Tip Ranks

Inhibrx Biosciences

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

Direxion S&P Biotech Bull 3X

SPDR S&P Biotech

VanEck Biotech ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

Stifel Nicolaus Sticks to Their Buy Rating for Inhibrx Biosciences Inc (INBX)